{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}]}],"title":"Any Adverse Event"},{"categories":[{"measurements":[{"groupId":"OG000","value":"36"},{"groupId":"OG001","value":"44"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":"Serious Adverse Events"},{"categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"41"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"}]}],"title":"Adverse Events Leading to Discontinuation"}],"denoms":[{"counts":[{"groupId":"OG000","value":"90"},{"groupId":"OG001","value":"86"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"}],"units":"Participants"}],"groups":[{"description":"vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks","id":"OG000","title":"Part 1: MGC018 2.0 mg (Arm A)"},{"description":"vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks","id":"OG001","title":"Part 1: MGC018 2.7 mg (Arm B)"},{"description":"abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.","id":"OG002","title":"Part 1: Control Arm"},{"description":"vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks","id":"OG003","title":"Part 2"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The Safety Population was used for this analysis.","reportingStatus":"POSTED","timeFrame":"Throughout the study, average duration of participation, 10 months.","title":"Number of Participants With Adverse Event (AEs), Serious AEs (SAEs), and AEs Leading to Study Treatment Discontinuation.","type":"SECONDARY","unitOfMeasure":"Participants"}